Heart failure (HF) imposes a large and growing burden on the population, with a prevalence that is projected to increase to more than 8 million adults by 2030. The high risk of morbidity and mortality ...
Results from the Phase 3 VICTOR trial and a pooled analysis of the VICTOR and VICTORIA trials were presented today at the ESC Congress 2025 and simultaneously published in The Lancet VERQUVO was ...
Please provide your email address to receive an email when new articles are posted on . Interatrial shunt implant lowered HF hospitalization risk for patients with HFrEF vs. placebo. However, patients ...
The role of ACE inhibitors in the management of HFPEF is less significant compared with their role in the management of heart failure with left ventricular systolic dysfunction. For patients with ...
A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking ...
Heart failure in which left ventricular ejection fraction recovers into the normal range has many unknowns. Andrew Perry, MD, discusses key management strategies with Jane Wilcox, MD, of Northwestern ...
ORLANDO, Fla., March 7, 2005 - Beta-blockers, medications that block the action of certain hormones on the heart, can benefit patients with certain serious heart problems such as diastolic heart ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results